Potential Evaluation of a Locally-Designed Wind-Pump System for Water Pumping to Irrigate Rice Crop Based on a Ten-Year Weather Data in the Philippines

Original Pape

An Overview of the Downdraft Rice Husk Gasifier Technology for Thermal and Power Applications

An overview of the downdraft rice husk gasifier (DDRHG) for thermal and power applications is herein presented. The different designs of the downdraft rice husk gasifier with reactor diameter ranging from 0.10 meter to 1.20 meter are discussed in detail. Smaller units of the DDRHG were found to have performed well in fixed bed. Larger units of the gasifier, on the other hand, are suited for moving-bed type making possible continuous operation without discharging and recharging the reactor. Present thermal applications of the gasifier includes: domestic cookstove, bakery oven, dryers, rotary kiln, steam boiler, and torrefyer. The DDRHG is also used to run surplus gasoline engines for driving water pump, micro-mill, and electric generator without any modification. The advantages and limitations of the gasifier as well as its environmental and socio-economic benefits over the use of conventional fossil-fueled systems are enumerated. At present, the investment cost for the gasifier ranges from PHP2,000 to 2,500.00 (USD 1 = PHP40.00) per kWt for thermal application and PHP20,000.00 to 30,000 per kWe for power generation. The cost of using the gasifier is much cheaper than that of the conventional fossil fuel and the investment can be recovered in a shorter period

Development of a Hydrous Ethanol Fuel Feeding Device for Spark-Ignition Engine

While the Philippine Biofuels Act of 2006 mandates the use of anhydrous bioethanol as blend for gasoline, the potential of hydrous ethanol as an alternative fuel for spark-ignition engines has not been fully realized. This study explored the possibility of using hydrous ethanol as fuel for spark-ignition engines with minimal modifications and without the need for gasoline blend. A fuel feeding device was developed to feed hydrous ethanol fuel into the intake manifold of the engine, bypassing the carburetor. By replacing the components that are not compatible with hydrous ethanol and installing a fuel feeding device developed at PhilRice, two spark-ignition engines were able to run solely on 80-95% hydrous ethanol fuel. The fuel economy was found to be a significant issue in the utilization of hydrous ethanol fuel as there is a 75% increase in fuel consumption when using hydrous ethanol. There is potential for hydrous ethanol to be used as fuel if it can be produced locally and sold at half the pump price of gasoline

Improving interMediAte Risk management. MARK study

<p>Abstract</p> <p>Background</p> <p>Cardiovascular risk functions fail to identify more than 50% of patients who develop cardiovascular disease. This is especially evident in the intermediate-risk patients in which clinical management becomes difficult. Our purpose is to analyze if ankle-brachial index (ABI), measures of arterial stiffness, postprandial glucose, glycosylated hemoglobin, self-measured blood pressure and presence of comorbidity are independently associated to incidence of vascular events and whether they can improve the predictive capacity of current risk equations in the intermediate-risk population.</p> <p>Methods/Design</p> <p>This project involves 3 groups belonging to REDIAPP (RETICS RD06/0018) from 3 Spanish regions. We will recruit a multicenter cohort of 2688 patients at intermediate risk (coronary risk between 5 and 15% or vascular death risk between 3-5% over 10 years) and no history of atherosclerotic disease, selected at random. We will record socio-demographic data, information on diet, physical activity, comorbidity and intermittent claudication. We will measure ABI, pulse wave velocity and cardio ankle vascular index at rest and after a light intensity exercise. Blood pressure and anthropometric data will be also recorded. We will also quantify lipids, glucose and glycosylated hemoglobin in a fasting blood sample and postprandial capillary glucose. Eighteen months after the recruitment, patients will be followed up to determine the incidence of vascular events (later follow-ups are planned at 5 and 10 years). We will analyze whether the new proposed risk factors contribute to improve the risk functions based on classic risk factors.</p> <p>Discussion</p> <p>Primary prevention of cardiovascular diseases is a priority in public health policy of developed and developing countries. The fundamental strategy consists in identifying people in a high risk situation in which preventive measures are effective and efficient. Improvement of these predictions in our country will have an immediate, clinical and welfare impact and a short term public health effect.</p> <p>Trial Registration</p> <p>Clinical Trials.gov Identifier: <a href="http://www.clinicaltrials.gov/ct2/show/NCT01428934">NCT01428934</a></p

Development and evaluation of four-wheel tractor-attached multi-crop planter for mechanized seeding of maize in the Philippines

The use of a multi-crop planter (MCP) attached to a compact 4-wheel tractor (4WT) is still not yet fully explored in the Philippines, despite the popularity of 4WT for land preparation in maize areas. A 4WT-attached MCP was developed for row seeding of rice, maize, and mungbean. This study evaluates the MCP adaptive model for maize in a field experiment and on-farm trials at two farmers’ fields during dry season. The MCP with seed metering plate having seven 12-mm diameter holes and 3-mm thickness had a seeding rate of 18.9 kg/ha which is within the targeted design range (15–20 kg/ha), a field capacity of 0.14 ha/h and field efficiency at 78%  in well-tilled-clay soil under controlled condition. In farmer’s fields, the MCP delivered seeding rates within and higher (19.6 and 24.9 kg/ha) than the prescribed design range. In reduced-tilled-loamy soil, field capacities and efficiencies ranged from 0.24–0.26 ha/h and 53–72%, respectively. Grain yields of MCP did not differ with farmer’s practice, but the seeding rate was significantly reduced by 35–38%. Compared with farmer’s practice, labor productivity with MCP increased by 37–51%. Economic analysis showed that owning and custom-hiring an MCP is viable. Investment cost can be recovered after 3.6 years and the benefit-cost ratio at 1.5.  This study underscore the potential benefit of using the MCP to improve the utilization of 4WT, increase the efficiency of planting maize in the Philippines, and reduce cost of production while maintaining grain yield

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI) : a phase 3, placebo-controlled, randomised trial

Background: Patients with stable coronary artery disease and diabetes with previous percutaneous coronary intervention (PCI), particularly those with previous stenting, are at high risk of ischaemic events. These patients are generally treated with aspirin. In this trial, we aimed to investigate if these patients would benefit from treatment with aspirin plus ticagrelor. Methods: The Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) was a phase 3 randomised, double-blinded, placebo-controlled trial, done in 1315 sites in 42 countries. Patients were eligible if 50 years or older, with type 2 diabetes, receiving anti-hyperglycaemic drugs for at least 6 months, with stable coronary artery disease, and one of three other mutually non-exclusive criteria: a history of previous PCI or of coronary artery bypass grafting, or documentation of angiographic stenosis of 50% or more in at least one coronary artery. Eligible patients were randomly assigned (1:1) to either ticagrelor or placebo, by use of an interactive voice-response or web-response system. The THEMIS-PCI trial comprised a prespecified subgroup of patients with previous PCI. The primary efficacy outcome was a composite of cardiovascular death, myocardial infarction, or stroke (measured in the intention-to-treat population). Findings: Between Feb 17, 2014, and May 24, 2016, 11 154 patients (58% of the overall THEMIS trial) with a history of previous PCI were enrolled in the THEMIS-PCI trial. Median follow-up was 3·3 years (IQR 2·8–3·8). In the previous PCI group, fewer patients receiving ticagrelor had a primary efficacy outcome event than in the placebo group (404 [7·3%] of 5558 vs 480 [8·6%] of 5596; HR 0·85 [95% CI 0·74–0·97], p=0·013). The same effect was not observed in patients without PCI (p=0·76, p interaction=0·16). The proportion of patients with cardiovascular death was similar in both treatment groups (174 [3·1%] with ticagrelor vs 183 (3·3%) with placebo; HR 0·96 [95% CI 0·78–1·18], p=0·68), as well as all-cause death (282 [5·1%] vs 323 [5·8%]; 0·88 [0·75–1·03], p=0·11). TIMI major bleeding occurred in 111 (2·0%) of 5536 patients receiving ticagrelor and 62 (1·1%) of 5564 patients receiving placebo (HR 2·03 [95% CI 1·48–2·76], p<0·0001), and fatal bleeding in 6 (0·1%) of 5536 patients with ticagrelor and 6 (0·1%) of 5564 with placebo (1·13 [0·36–3·50], p=0·83). Intracranial haemorrhage occurred in 33 (0·6%) and 31 (0·6%) patients (1·21 [0·74–1·97], p=0·45). Ticagrelor improved net clinical benefit: 519/5558 (9·3%) versus 617/5596 (11·0%), HR=0·85, 95% CI 0·75–0·95, p=0·005, in contrast to patients without PCI where it did not, p interaction=0·012. Benefit was present irrespective of time from most recent PCI. Interpretation: In patients with diabetes, stable coronary artery disease, and previous PCI, ticagrelor added to aspirin reduced cardiovascular death, myocardial infarction, and stroke, although with increased major bleeding. In that large, easily identified population, ticagrelor provided a favourable net clinical benefit (more than in patients without history of PCI). This effect shows that long-term therapy with ticagrelor in addition to aspirin should be considered in patients with diabetes and a history of PCI who have tolerated antiplatelet therapy, have high ischaemic risk, and low bleeding risk

Global economic burden of unmet surgical need for appendicitis

Background There is a substantial gap in provision of adequate surgical care in many low- and middle-income countries. This study aimed to identify the economic burden of unmet surgical need for the common condition of appendicitis. Methods Data on the incidence of appendicitis from 170 countries and two different approaches were used to estimate numbers of patients who do not receive surgery: as a fixed proportion of the total unmet surgical need per country (approach 1); and based on country income status (approach 2). Indirect costs with current levels of access and local quality, and those if quality were at the standards of high-income countries, were estimated. A human capital approach was applied, focusing on the economic burden resulting from premature death and absenteeism. Results Excess mortality was 4185 per 100 000 cases of appendicitis using approach 1 and 3448 per 100 000 using approach 2. The economic burden of continuing current levels of access and local quality was US $92 492 million using approach 1 and$73 141 million using approach 2. The economic burden of not providing surgical care to the standards of high-income countries was $95 004 million using approach 1 and$75 666 million using approach 2. The largest share of these costs resulted from premature death (97.7 per cent) and lack of access (97.0 per cent) in contrast to lack of quality. Conclusion For a comparatively non-complex emergency condition such as appendicitis, increasing access to care should be prioritized. Although improving quality of care should not be neglected, increasing provision of care at current standards could reduce societal costs substantially

Global economic burden of unmet surgical need for appendicitis

Background There is a substantial gap in provision of adequate surgical care in many low- and middle-income countries. This study aimed to identify the economic burden of unmet surgical need for the common condition of appendicitis. Methods Data on the incidence of appendicitis from 170 countries and two different approaches were used to estimate numbers of patients who do not receive surgery: as a fixed proportion of the total unmet surgical need per country (approach 1); and based on country income status (approach 2). Indirect costs with current levels of access and local quality, and those if quality were at the standards of high-income countries, were estimated. A human capital approach was applied, focusing on the economic burden resulting from premature death and absenteeism. Results Excess mortality was 4185 per 100 000 cases of appendicitis using approach 1 and 3448 per 100 000 using approach 2. The economic burden of continuing current levels of access and local quality was US $92 492 million using approach 1 and$73 141 million using approach 2. The economic burden of not providing surgical care to the standards of high-income countries was $95 004 million using approach 1 and$75 666 million using approach 2. The largest share of these costs resulted from premature death (97.7 per cent) and lack of access (97.0 per cent) in contrast to lack of quality. Conclusion For a comparatively non-complex emergency condition such as appendicitis, increasing access to care should be prioritized. Although improving quality of care should not be neglected, increasing provision of care at current standards could reduce societal costs substantially